Correction to: Infect Dis Ther (2023) 12:2725–2743 https://doi.org/10.1007/s40121-023-00891-1
In Table 2, one of the subheaders was missed in the original article. The corrected Table 2 is given below. Original article has been corrected.
Table 2
SARS-CoV-2 antibodies at baseline, by treatment arm in the modified intention-to-treat population
Molnupiravir | Placebo | Total | ||||
|---|---|---|---|---|---|---|
Participants in population | N = 709 | N = 699 | N = 1408 | |||
Nucleocapsid antibodies | ||||||
Positive, n (%) | 139 | (19.6) | 151 | (21.6) | 290 | (20.6) |
Negative, n (%) | 557 | (78.6) | 535 | (76.5) | 1092 | (77.6) |
Unknowna, n (%) | 13 | (1.8) | 13 | (1.9) | 26 | (1.8) |
Neutralizing anti-spike antibodies | ||||||
Positive, n (%) | 190 | (26.8) | 188 | (26.9) | 378 | (26.8) |
Negative, n (%) | 513 | (72.4) | 506 | (72.4) | 1019 | (72.4) |
Unknowna, n (%) | 6 | (0.8) | 5 | (0.7) | 11 | (0.8) |
Anzeige
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.